Related Experiment Videos
Acceleration of conduction within an accessory pathway with propafenone
A N Sulke1, P Holt, G E Sowton
1Department of Cardiology, Guy's Hospital, London, U.K.
International Journal of Cardiology
|July 1, 1990
Summary
Propafenone, a Class IC antiarrhythmic drug, can dangerously accelerate heart conduction in patients with Wolff-Parkinson-White syndrome. This previously undescribed pro-arrhythmic effect highlights a potential risk with increased propafenone use.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Wolff-Parkinson-White syndrome is characterized by an accessory pathway that can lead to supraventricular tachycardia.
- Class IC antiarrhythmic agents, like propafenone, are used to manage cardiac arrhythmias.
- Routine electrophysiological studies are crucial for diagnosing and understanding accessory pathway function.
Observation:
- A case study involving a patient with Wolff-Parkinson-White syndrome undergoing an electrophysiological study.
- Administration of propafenone during the study.
- Monitoring of cardiac conduction through the accessory pathway.
Findings:
- Propafenone induced a dangerous acceleration of conduction through the accessory pathway.
- This pro-arrhythmic effect of propafenone was not previously documented.
- The findings are significant given the increasing use of propafenone.
Implications:
- Clinicians should be aware of the potential pro-arrhythmic risk of propafenone in Wolff-Parkinson-White syndrome patients.
- This case underscores the importance of careful drug selection and monitoring during electrophysiological studies.
- Further research may be warranted to elucidate the mechanisms behind this adverse effect.